Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay by Wan, Jun et al.
 
 
 University of Groningen
Whole blood thrombin generation profiles of patients with cirrhosis explored with a near
patient assay
Wan, Jun; Roberts, Lara N.; Hendrix, Wasiliki; Konings, Joke; Ow, Tsai-Wing; Rabinowich,
Liane; Barbouti, Omar; De   Laat, Bas; Arya, Roopen; Patel, Vishal C.
Published in:
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
DOI:
10.1111/jth.14751
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Wan, J., Roberts, L. N., Hendrix, W., Konings, J., Ow, T-W., Rabinowich, L., Barbouti, O., De Laat, B.,
Arya, R., Patel, V. C., Roest, M., Lisman, T., & Bernal, W. (2020). Whole blood thrombin generation profiles
of patients with cirrhosis explored with a near patient assay. JOURNAL OF THROMBOSIS AND
HAEMOSTASIS, 18(4), 834-843. https://doi.org/10.1111/jth.14751
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
834  |    J Thromb Haemost. 2020;18:834–843.wileyonlinelibrary.com/journal/jth
 
Received: 14 November 2019  |  Accepted: 27 January 2020
DOI: 10.1111/jth.14751  
O R I G I N A L  A R T I C L E
Whole blood thrombin generation profiles of patients with 
cirrhosis explored with a near patient assay
Jun Wan1,2  |   Lara N. Roberts3  |   Wasiliki Hendrix1 |   Joke Konings1,2 |    
Tsai-Wing Ow4 |   Liane Rabinowich4 |   Omar Barbouti4 |   Bas de Laat1,2 |   Roopen Arya3 | 
Vishal C. Patel4,5,6  |   Mark Roest1,2 |   Ton Lisman7  |   William Bernal4,5
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and 
Haemostasis
Manuscript handled by: Robert Gosselin 
Final decision: Robert Gosselin, 27 January 2020 
1Synapse Research Institute, Maastricht, the 
Netherlands
2Cardiovascular Research Institute, 
Maastricht University, Maastricht, the 
Netherlands
3King's Thrombosis Centre, Department of 
Haematological Medicine, King's College 
Hospital, London, UK
4Institute of Liver Studies, King's College 
Hospital, London, UK
5School of Immunology and Microbial 
Sciences, Faculty of Life Sciences and 
Medicine, King's College London, London, 
UK
6Institute of Hepatology London, 
Foundation for Liver Research, London, UK
7Surgical Research Laboratory, Section 
of Hepatobiliary Surgery and Liver 
Transplantation, Department of Surgery, 
University of Groningen, University 
Medical Center Groningen, Groningen, the 
Netherlands
Correspondence
William Bernal, Institute of Liver Studies, 
King's College Hospital, London, UK.
Email: william.bernal@kcl.ac.uk
Ton Lisman, Department of Surgery, 




Background and Aims: Patients with cirrhosis have a rebalanced hemostasis, often 
with normal or elevated thrombin-generating (TG) capacity in plasma. Whole blood 
(WB) TG allows faster determination and, importantly, includes the influence of all 
circulating blood cells. We aimed to study the TG profile of patients with cirrhosis in 
WB and in platelet poor plasma.
Methods: Thrombin-generating capacity in WB and plasma were assessed with a 
near-patient WB-TG assay and the calibrated automated thrombinography assay, 
respectively. TG assays were tested in presence and absence of thrombomodulin. 
Conventional coagulation tests were also performed.
Results: Thirty-four patients with cirrhosis and twenty-two controls were analyzed. 
Compared with controls, patients had substantially deranged results in conventional 
coagulation tests. Comparable WB-TG capacity (endogenous thrombin potential until 
peak, ETPp) but significantly lower peak thrombin were found in patients, and these 
results persisted when thrombomodulin was present. TG of the patients was more 
resistant to thrombomodulin than controls in both WB and plasma, although the in-
hibitory effect of thrombomodulin was drastically weaker in WB than in plasma. The 
peak of WB-TG in patients correlated moderately with their hematocrit and platelet 
count. Significant correlations were found between TG results in WB and plasma.
Conclusions: The WB-TG assay shows a normal to hypocoagulable state in patients 
with cirrhosis with a decreased anticoagulant activity of TM compared to plasma-TG. 
The clinical value of this assay needs further validation.
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1  | INTRODUC TION
Patients with liver dysfunction may acquire substantial alterations 
in their hemostatic system because the liver is responsible for the 
synthesis of the majority of hemostatic proteins. Conventional co-
agulation tests, such as the prothrombin time (PT) and the activated 
partial thromboplastin time (APTT), are frequently prolonged in 
patients with cirrhosis, suggesting a generalized tendency toward 
bleeding. However, PT and APTT are only sensitive to changes in 
the procoagulant pathways, therefore reflecting only the abnor-
malities of the pro-coagulant proteins in cirrhosis, but providing 
little information about the anticoagulant pathways including an-
tithrombin and proteins of the protein C pathway. Anticoagulant 
pathways may also be impaired in cirrhosis.1-3 Clinical data show 
that cirrhotic patients are not “auto-anticoagulated,” but rather 
have equal or even higher thrombotic risk than patients without 
liver disease.2,4,5 These observations have led to the concept of re-
balanced hemostasis to explain the complex coagulation profiles in 
patients with cirrhosis.6-8 Although a hemostatic balance is reached 
in cirrhosis, this equilibrium is more fragile and may easily tip to-
ward a hypo- or hypercoagulable state; however, traditional coagu-
lation tests are not suitable to assess the functioning coagulation 
profiles in these patients.
Thrombin generation (TG) is a sophisticated laboratory test 
capable of assessing the complex interplay between pro- and an-
ti-coagulant pathways, thus reflecting the function of the global 
hemostatic system. Modern TG assays, such as the calibrated 
automated thrombinography (CAT) assay, enable continuous TG 
measurement in plasma and have been shown to be predictive of 
thrombotic or bleeding risk in various coagulation disorders.9,10 
The onset, rate, and total capacity of TG in a given sample are 
represented by different parameters of a TG curve, ie, the lag 
time, peak thrombin, and endogenous thrombin potential (ETP), 
respectively.9 By adding an activator of the anticoagulant pro-
tein C pathway, eg, thrombomodulin (TM) or Protac, a TG assay 
reflects the balance between all pro- and anticoagulant drivers. 
Studies using the TM-modified TG assays have revealed that the 
impaired procoagulant system is compensated for by the reduced 
anti-coagulant function in liver disease. This is reported to occur 
in both chronic liver disease and acute liver injury/failure.6,7,11,12 
These observations are in agreement with the clinical observa-
tions that there is no increased hemostasis-related bleeding risk 
for most patients.
Although the TM-modified TG assay was a crucial step forward 
in understanding the net effects of the multiple alterations in co-
agulation in cirrhosis, there are still several questions that remain 
to be answered. Standard TG assays are performed with platelet 
poor plasma (PPP) in the absence of blood cells, with synthetic 
phospholipids (PL) added to provide surfaces for the assembly of 
tenase and prothrombinase. These conditions may be different 
from physiological coagulation, which depends on the surfaces 
provided by activated platelets and most probably also erythro-
cytes.13-16 During physiological coagulation there is a continuous 
interplay among coagulation initiation, platelet activation, propa-
gation of coagulation, and erythrocyte suppletion.13 In cirrhosis, 
anemia and thrombocytopenia are common and this could lead to 
reduced availability of procoagulant surfaces, which could poten-
tially limit the rate and even capacity of TG. A study assessing TG 
in the platelet rich plasma (PRP) of cirrhotic patients demonstrated 
that platelet count is an important determinant of the ETP.17 
Although PRP-TG reflects the influence of platelets, it does not 
measure the additional impact of other blood cells. On the con-
trary, whole blood (WB)-TG includes the influence of all circulating 
blood cells on TG.18 Another practical advantage of performing 
WB-TG over plasma TG is that no centrifugation is needed, avoid-
ing potential pre-analytical variation and allowing faster results, 
which is crucial for point-of-care applications in critically ill or ac-
tively bleeding patients.18
We have previously developed a near patient WB-TG assay 
by using a miniaturized TG device and a microfluidic chip.19 This 
assay was shown to be predictive of postoperative blood loss in 
patients undergoing elective cardiac surgery.19 The short turn-
around time and compact size of the near patient WB-TG assay 
system allows possible deployment outside a specialized labo-
ratory environment. In this study, for the first time, we studied 
WB-TG profiles of a cohort of patients with cirrhosis by using the 
near patient assay.
2  | MATERIAL S AND METHODS
2.1 | Patients and healthy controls
Patients with cirrhosis and healthy controls were recruited at King's 
College Hospital NHS Foundation Trust, London. The study was ap-
proved by the London (Camden & Islington) Research and Ethics 
Committee (REC number: 11/LO/0706) and the local Research 
and Development department at King's College Hospital NHS 
Foundation Trust. All participants provided written informed con-
sent prior to study entry; where this was not possible, consultee 
permissions were obtained from their next of kin. Subjects were 
excluded from the analysis if they had acute liver failure or had re-
ceived any anticoagulant or anti-platelet therapy.
Essentials
• Plasma thrombin generation (TG) tests support rebal-
anced hemostasis in patients with cirrhosis.
• Whole blood (WB)-TG profile in cirrhosis was tested by 
a near patient assay for the first time.
• Patients with cirrhosis have normal WB-TG capacity but 
with a lower rate.
• The anticoagulant effect of thrombomodulin was drasti-
cally weaker on WB-TG than on plasma-TG.
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2.2 | Blood collection and plasma preparation
Blood was collected into vacuum tubes (1 volume 0.109 mol/L triso-
dium citrate to 9 volumes blood; VACUETTE®, Greiner Bio-One). 
The blood was kept at room temperature and used within 4 hours 
after collection. PPP was prepared by double centrifugation of cit-
rated WB at 2840 g for 10 minutes. Plasma was aliquoted and frozen 
at −80°C before analysis.
2.3 | WB-TG as measured with a modified near 
patient assay
WB-TG was measured on a previously described miniaturized TG 
device19 and a newly modified microfluidic chip. The previous chip, 
which was made from methyl methacrylate-acrylonitrile-butadie-
nestyrene (MABS), suffered from occasional fluid leakage.19 We 
adopted a new design for the chip, which consisted of two pieces 
of polydimethylsiloxane (PDMS) with a porous matrix disc of 5 mm 
in diameter and 190 µm in thickness (grade 589/1; Whatman) in 
between. The two PDMS parts were prepared in house by mix-
ing 10 parts of polymer with 1 part of curing agent (Sylgard 184, 
Dow Corning) and then solidified in an aluminum mold at 100°C 
for 90 minutes. After treatment in a plasma cleaner (PDC-32G-2, 
Harrick Plasma) for 15 minutes, the two PDMS parts were then as-
sembled with filter paper in the center of the chamber between the 
two PDMS parts. Permanent bonds formed between the two PDMS 
parts, hence leakage was effectively prevented.
Citrated blood (15 µL) was mixed with 15 µL trigger solution 
containing 600 µmol/L fluorogenic thrombin substrate (ZGGR)2-
Rhodamine 110 (P2Rho; Mercachem BV), 5 pmol/L recombinant 
human tissue factor (TF; Siemens Healthcare), and 33.4 mmol/L 
CaCl2 in buffer containing 20 mmol/L HEPES, 140 mmol/L NaCl, 
and 5 g/L bovine serum albumin (Sigma) with a pH of 7.35. Fifteen 
microliters of the above mixture was immediately injected into the 
inlet of the microfluidic chip and the fluorescence measurement was 
started. An additional measurement was also done with soluble TM 
(U-protein Express) added into the TF-containing trigger solution. 
The final concentrations were 50% volume blood, 2.5 pmol/L TF, 
16.7 mmol/L CaCl2 and 300 µmol/L P2Rho in the presence or ab-
sence of 150 nmol/L TM. This TM concentration was chosen based 
on dose-response experiments (Figure S1 in supporting informa-
tion). For every blood sample an independent calibration experiment 
was performed in which 15 µL α2-macroglobulin–thrombin complex 
(α2M-T, ie, the calibrator, prepared as previously described
9) was 
added to 30 µL of blood and substrate mixture; then 15 µL of the 
above mixture was injected into the chip and measured. The fluores-
cence signal was recorded with γex = 470 nm and γem = 520 nm. The 
assay was performed at 37°C.
From the fluorescence data the WB-TG parameters were cal-
culated using a Chapman-Richard growth (CRG)-based calculation 
method as previously described.19 TG parameters selected for the 
analyses include the lagtime (the time from triggering coagulation 
until thrombin is detectable; min), time-to-peak (TTP, the time 
from initiation until the highest transient thrombin concentra-
tion; min), peak (the highest transient thrombin concentration; 
nmol/L) and endogenous thrombin potential until the thrombin 
peak (ETPp, ie, the area under the TG curve until the thrombin 
peak is reached; nmol × min/L). The TG parameters tested in the 
presence of TM are depicted as lagtime™+, TTP™+, peak™+, and 
ETPp™+, respectively. The interassay coefficient of variation (CV) 
of the assay was determined by testing six independent measure-
ments per donor, the average inter-assay variation in five donors 
was 7.2%, 2.6%, 14.4%, and 13.7% for the lagtime, TTP, peak, and 
ETPp, respectively.
2.4 | PPP-TG measurement with the CAT assay
TG in PPP was measured with the CAT technique on a Fluoroskan 
Microplate Fluorometer (Thermolabsystems OY) as originally de-
scribed.9 The final concentration of TF was 5 pm with 4 µmol/L PL in 
the absence or presence of 10 nmol/L TM. The concentration of TM 
was chosen to inhibit TG by 50% in normal pooled plasma (NPP). TG 
parameters were calculated with Thrombinoscope software version 
5.0, and TG parameters including the lagtime, TTP, peak, and ETP 
were chosen for further analyses.
In each run of TG measurement, NPP was also measured on 
the same plate. The ETP and peak values of the study subjects 
were normalized as the percentage of the ETP and peak of the 
NPP tested without TM in the same run, respectively. For better 
standardization and comparison, the PPP-TG parameters of sam-
ples measured in the presence of TM, including peak™+ and ETP™+, 
were also normalized as the percentage of the ETP and peak of the 
NPP tested without TM in the same run. The preparation of the 
NPP has been described previously.20 Blood from 116 healthy adult 
volunteers who gave written consent and did not take any antico-
agulant or antiplatelet drugs for at least 2 weeks before blood draw 
was collected at Maastricht University Medical Center. After an 
initial centrifugation step (2500 g, 5 minutes) plasma was pooled, 
followed by ultracentrifugation (100 000 g, 10 minutes). Aliquots 
of 500 µL were snap-frozen in liquid nitrogen and stored at −80°C 
until analysis.
2.5 | Standard laboratory measurements
All coagulation assays were performed on the automated ana-
lyzer STA-R as previously described.12 Reagents were obtained 
from Diagnostica Stago for all coagulation assays which were per-
formed on the automated analyzer STA-R Evolution (Diagnostica 
Stago). APTT and international normalized ratio (INR) were meas-
ured by coagulation-based assays, with STA-Cephascreen and 
STA-Neoplastine, respectively. Clauss methodology was utilized to 
quantify fibrinogen with STA-Fibrinogen. Antithrombin activity was 
measured by a chromogenic substrate method, with STA-Stachrom 
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ATIII. Factor (F) II, VIII, and X were quantified with STA-deficient II, 
VIII, X immune-depleted plasmas using coagulation-based assays. 
Full blood cell count analysis was performed by a flow cytometry 
method and hemoglobin by a colorimetric method, with reagents 
from Bayer Diagnostics and the Advia 2120 automated hematology 
analyzer (Bayer Diagnostics).
2.6 | Statistics
Statistical analyses were performed with SPSS version 25 and 
graphs were generated using GraphPad Prism software version 6. 
Normality of the data was assessed using the Shapiro-Wilk test. 
Data are represented as median with interquartile range (IQR). 
Comparisons between two independent groups were performed 
with the Mann-Whitney test. Fisher's exact test was used to com-
pare nominal data between groups. The Spearman test was used for 
the correlation analysis. A two-sided P-value < .05 was considered 
statistically significant.
3  | RESULTS
3.1 | Characteristics of patients and controls
In total 34 patients with cirrhosis and 22 healthy donors were 
included in the analyses. As shown in Table 1, the patient group 
was older (P < .001) but had similar gender distribution compared 
with controls. The etiology of cirrhosis included alcohol related 
liver disease (n = 17), non-alcoholic fatty liver disease (n = 7), viral 
hepatitis (n = 3), and primary sclerosing cholangitis (n = 3). In addi-
tion, drug induced liver injury, primary biliary cirrhosis, non-alco-
holic steatohepatitis, and autoimmune disease were each found 
in one patient.
Four patients were classified as Child-Pugh class A, 18 patients 
were in class B, and 12 patients in class C. The median Model for 
End-Stage Liver Disease (MELD) score of the patients was 17.5 (IQR: 
14.3-23.8). Twenty-six patients had acutely decompensated (AD) 
cirrhosis, with a CLIF-AD score of 51 (45-53). Six patients fulfilled 
criteria for chronic liver failure (ACLF), of which three patients had a 
CLIF-ACLF grade 2, three patients had grade 3.21,22
3.2 | Conventional coagulation tests and cell counts
Patients with cirrhosis had significantly distorted coagulation pro-
files compared to healthy controls, as shown in Table 1. Patients 
had significantly higher INR and longer APTT (P < .001 for both). 
Lower levels of both pro- and anticoagulant factors were found 
in the patients, such as FII, FX, and antithrombin, except FVIII, 
which was higher (P < .001 for all factors compared with con-
trol). Clauss fibrinogen was comparable between the patients and 
controls.
Platelet count and hematocrit of the patient group were notice-
ably lower than the local reference ranges. The median (IQR) values 
in the patients were 92.5 (59-159) × 109/L and 0.32 (0.27-0.37) for 
platelet count and hematocrit, respectively, whereas the respective 
local reference ranges were 150-450 × 109/L and 0.36-0.50. The 
white blood cell counts of the patients were within the local refer-
ence range. The cell counts of the controls were not measured.
3.3 | WB-TG profiles
Figure 1A shows representative WB-thrombograms of the patients 
and controls. As summarized in Table 2 and shown in Figure 1B, pa-
tients had significantly longer lagtime and TTP than controls (P < .01 
for both; Figure 1B). The peak thrombin value was substantially lower 
in patients than in controls (median values were 118 and 179 nmol/L 
for patients and controls, respectively; P < .001). However, the ETPp 
was not significantly different between the patients and controls 
(230 [196-294] versus 247 [222-280] nmol × min/L, respectively; 
P = .356).
The addition of 150 nmol/L TM into the WB-TG assay sub-
stantially prolonged the lagtime in both patients and controls to a 
similar extent of 37% (P = .926). Conversely, the added TM only ex-
hibited a weak inhibitory effect on ETPp. TM-induced inhibition on 
the ETPp was slightly lower in patients at 10.3 (2.0-19.9) % than in 
controls at 18.9 (12.7-27.5)% (P = .048). In the presence of TM, the 
ETPp™+ was still similar between patients and controls (P = .709), 
whereas the peak™+ remained lower in patients (P < .001; Table 2 
and Figure 1C).
3.4 | PPP-TG profiles
We obtained TG data from 28 out of the 34 patients, because PPP 
was not collected from 5 patients, and no TG curve was obtained 
from 1 of the patients. When PPP-TG was measured in the absence 
of TM, comparable lagtime and TTP values were found in patients 
and controls. The peak and ETP were slightly but significantly lower 
(12.2% and 14% lower in median values, respectively) in patients 
(Table 3 and Figure 2A). When PPP-TG was tested in the presence 
of TM, the peak™+ and ETP™+ values of the patient plasma were 
significantly higher than the controls (35.8% and 58.7% higher in 
median values; P = .009 and P < .001, respectively; Table 3 and 
Figure 2B).
3.5 | Correlations of TG parameters with 
other factors
We explored a possible relation between TG parameters and other 
factors. Age of the study subjects was counterintuitively correlated 
with longer lagtime (r = .435) and TTP (r = .405), as well as lower peak 
(r = −.301) of WB-TG, but not with ETPp (r = .021, P = .879; Table 4). 
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The PPP-TG parameters in the presence of TM also showed moder-
ate to weak correlations with age, including the lagtime™+ (r = .394) 
and ETP™+ (r = .284).
Moderate to weak correlations were found between WB-TG pa-
rameters in the absence of TM with corresponding PPP-TG parame-
ters in absence of TM, including the lagtime (r = .282), peak (r = .468), 
and ETP (r = .415; Table 4).
Positive correlations were found between the hematocrit of pa-
tients and their WB-TG parameters, including the peak (Spearman 
r = .434), ETPp (r = .417) (Table 4), and peak™+ (r = .374). The peak 
value was also positively correlated with the platelet count of the 
patients (r = .559). The platelet count showed weaker correlation 
with the ETPp (r = .304, P = .085).
In addition, the platelet count was positively correlated with some 
parameters of the PPP-TG, including the lagtime (r = .529, P = .004), 
ETP (r = .45, P = .016), and lagtime™+ (r = .528, P = .004). No significant 
correlation was found between hematocrit and PPP-TG parameters.
Cirrhosis severity, as represented by the Child-Pugh classifica-
tion and MELD score, was correlated with longer lagtime and lower 
peak of WB-TG, both in the absence and presence of TM (P < .05 for 
all correlations). The above scores were also correlated with lower 
peak of PPP-TG (P < .05 for both correlations).
 
Patients Controls
P valuen Median (IQR) n Median (IQR)
Age, years 34 58 (53.3–63) 22 32.5 (28–39.5) <.001
Gender: female 34 10 (29.4%) 22 12 (54.5%) .093
Etiology
ALD  17 (50%)    
NAFLD  7 (20.6%)    
Viral hepatitis  3 (8.8%)    
PSC  3 (8.8%)    
Other  4 (11.8%)    
Laboratory tests
Sodium, mmol/L 34 136 (134–138)    
Creatinine, µmol/L 34 79 (68–109)    
Albumin, g/L 34 31.5 (26–34)    
Bilirubin, µmol/L 34 43.5 (23.3–109)    
Child-Pugh classification
A  4 (11.8%)    
B  18 (52.9%)    
C  12 (35.3%)    
MELD score 34 17.5 (14.3–23.8)    
Coagulation parameters
Platelet, x109/L 34 92.5 (59–159)    
Hematocrit 34 0.32 (0.27–0.37)    
Hemoglobin, g/L 34 99.5 (88–118)    
White cell count, 
x109/L
34 4.65 (3.43–6.53)    
INR, ratio 25 1.47 (1.26–1.81) 20 1.02 (0.98–1.07) <0.001
APTT, second 22 38.8 (35.2–43.3) 19 29.4 (28.6–31.5) <.001
Fibrinogen, g/L 25 2.8 (1.72–4.15) 20 2.8 (2.5–3.12) .802
FII, % 25 53 (42–72) 20 98 (88.3–105) <.001
FVIII, % 26 242 (210–284) 20 118 (93–175) <.001
FX, % 25 55 (47–67) 20 93.5 (87.8–108) <.001
AT, % 27 57 (38–81.5) 20 104.5 (99–107.5) <.001
Note: Values are median (interquartile range) or number (percentage).
Abbreviations: ALD, alcoholic liver disease; APTT, activated partial thromboplastin time; FII, factor 
II; FVIII, factor VIII; FX, factor X; INR, international normalized ratio; IQR, interquartile range; 
MELD, the Model for End-Stage Liver Disease; NAFLD, nonalcoholic fatty liver disease; PSC, 
primary sclerosing cholangitis
TA B L E  1   Characteristics and 
coagulation profiles of patients with 
cirrhosis and healthy controls
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4  | DISCUSSION
We studied the TG profiles of patients with cirrhosis in WB using a 
near patient WB-TG assay and in PPP with the standard CAT assay. 
WB-TG results showed normal TG capacity but lower TG rate in 
patients with cirrhosis, suggesting normal- to hypocoagulability; 
whereas TM-modified PPP-TG suggested hypercoagulability, with 
both higher TG capacity and rate found in cirrhosis. The WB-TG 
parameters showed moderate correlations with platelet count and 
hematocrit, as well as the standard PPP-TG parameters. We also 
surprisingly found that WB-TG is less sensitive to the anticoagulant 
function of TM than PPP-TG.
TG assays have been extensively used to study the coagu-
lation profiles of patients with liver disease, and studies using 
TM-modified plasma TG assay have shown intact or elevated TG 
potential in cirrhosis, supporting the concept that these patients 
have re-balanced hemostasis.6,23-27 However, until now all studies 
on TG profiles in these patients were performed in plasma samples, 
which has limitations, such as the requirement for a specialized lab-
oratory environment, a longer turnaround time for results, and the 
inability to study the effect of most blood cells (except platelets) 
on TG. Until now there are no published data of WB-TG measure-
ments in liver disease patients. Although whole blood viscoelastic 
assays have been tested in liver disease patients and shown addi-
tional value in reducing blood product administration, they do not 
assess the protein C pathway, and their ability to predict clinical 
outcome is still unclear.28,29
Using the near patient WB-TG assay, we observed that the en-
dogenous thrombin generating potential (ETPp) values of patients 
with cirrhosis, regardless of the presence/absence of TM, were in 
the same range as in healthy controls, suggesting that these patients 
had normal thrombin-generating capacity. The standard PPP-TG 
results add to the growing literature that hypocoagulable state is 
suggested when TG is tested without activating the protein C path-
way, whereas hypercoagulable state is found when the function of 
F I G U R E  1   Whole blood thrombin generation (WB-TG) profiles 
of the study subjects. The whole blood thrombin generation 
profiles of patients with cirrhosis and healthy controls were 
studied with a near patient assay at 2.5 pmol/L tissue factor. 
A, representative curves of WB-TG of the patients (n = 34) and 
controls (n = 22) are shown. WB-TG parameters in the absence 
and presence of thrombomodulin (TM) are shown in (B) and 
(C), respectively. The Mann-Whitney test was used to compare 
between groups, P values are shown. Bars in the graph represent 
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 Patients (n = 34) Controls (n = 22) P value
WB-TG parameters in the absence of TM
Lagtime (min) 5.1 (4.2–6.1) 3.3 (2.8–3.9) <.001
TTP (min) 8.4 (7.3–9.9) 5.7 (5.1–6.8) <.001
Peak (nmol/L) 118 (98–145) 179 (164–192) <.001
ETPp (nmol × min/L) 230 (196–294) 247 (222–280) .356
WB-TG parameters in the presence of TM
Lagtime™+ (min) 6.6 (6.1–9.3) 4.6 (4.1–5.2) <.001
TTP™+ (min) 10.9 (9.8–15) 8.1 (7.1–8.9) <.001
Peak™+ (nmol/L) 79.7 (65.1–96.2) 115 (104–127) <.001
ETPp™+ (nmol × min/L) 205 (181–238) 195 (177–233) .709
Note: Values are median (interquartile range).
Abbreviations: ETPp, endogenous thrombin potential until the thrombin peak; TG, thrombin 
generation; TM, thrombomodulin; TTP, time to peak; WB, whole blood
TA B L E  2   Whole blood thrombin 
generation profiles of patients and 
controls
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the anticoagulant protein C pathway is included in TG by adding TM 
into the test.6,24-27,30 These results indicate that cirrhosis does not 
necessarily result in a hypocoagulable state as suggested by their 
lower procoagulant factor levels and prolonged PT and APTT, thus 
reinforcing that prophylactic administration of fresh-frozen plasma 
according to their PT/APTT is not required.31,32
Of note, although the TG capacity of cirrhotic patients is com-
parable to the controls, their peak thrombin level is discordantly 
lower, suggesting a hypocoagulable state. The ETP and peak are 
usually well correlated in PPP-TG, but their relation in WB has not 
been extensively explored. The above discordance might be due 
to a differential effect of low cell count on peak and ETPp. In our 
experience and in literature, the platelet count much more strongly 
affects the peak of PRP-TG than the ETP. In fact the ETP plateaued 
once the platelet count reached a certain level (approximately 
100*109 platelets/L) but the peak still increases with further as-
cending platelet counts.33 The influence of erythrocyte count on 
WB-TG is less explored, but a recent study found that at a nor-
mal platelet concentration of 200*109/L the peak of WB-TG was 
significantly augmented by increasing hematocrit from 0.2 to 0.45, 
whereas the ETP was largely unchanged.34 Therefore, the lower 
counts of platelets and erythrocytes in cirrhotic patients might 
have induced differential impact on the peak and ETP of WB-TG, 
and caused the above-observed discordance. Platelets and eryth-
rocytes are involved in TG via many mechanisms, including but not 
limited to their expression of procoagulant surface.13,14,35-37 The 
activation/function of platelets in cirrhosis remains controversial.38 
It has been reported that platelets are defective in aggregate for-
mation, have a storage pool defect and defective transmembrane 
signaling in cirrhosis,39 while other studies have reported that 
blood cells from cirrhotic patients have abnormally high levels 
of PS exposure and this may contribute to their hypercoagulable 
state.40,41 Moreover, erythrocytes, as the most abundant cells in 
circulation, may also indirectly impact TG by augmenting platelet 
activation.36,42 Overall the function of blood cells in TG of liver dis-
ease patients is still poorly characterized and this WB-TG assay has 
potential to improve insight into this topic.
Interestingly, WB-TG showed less sensitivity to the anticoagulant 
function of TM than PPP-TG. A high dose (150 nmol/L) of TM only 
induced weak inhibition on WB-TG, as the ETPp in patients and con-
trols was only inhibited by 10.3% and 18.9%, respectively. Although 
the WB-TG of cirrhotic patients showed increased resistance to TM 
TA B L E  3   Plasma thrombin generation profiles in the absence 
and presence of thrombomodulin
 Patients (n = 28) Controls (n = 22) P value
PPP-TG parameters in the absence of TM
Lagtime 
(min)
2.3 (2–3.3) 2.3 (2.3–2.6) .627
TTP (min) 4.3 (3.8–5.3) 4.7 (4.3–5.1) .082
Peak (% of 
NPP)
113 (89.1–128) 129 (115–137) .019
ETP (% of 
NPP)
90.5 (82.3–101) 105 (96–121) .001
PPP-TG parameters in the presence of TM
Lagtime™+ 
(min)
2.7 (2.3–3.6) 2.4 (2.3–2.7) .043
TTP™+ (min) 4.5 (4.1–5.3) 4.3 (4–4.5) .102
Peak™+ (% 
of NPP)
96.9 (74.6–108) 71.4 (52.1–83.1) .009
ETP™+ (% of 
NPP)
75.8 (67.4–84.5) 47.8 (38.1–58) <.001
Note: Values are median (interquartile range); the peak and ETP values 
both in the absence and presence of TM were all normalized as the 
percentage of that of the NPP tested without TM in the sample run.
Abbreviations: ETP, endogenous thrombin potential; NPP, normal 
pooled plasma; PPP, platelet poor plasma; TG, thrombin generation; TM, 
thrombomodulin; TTP, time to peak
F I G U R E  2   Plasma thrombin generation profiles of the study 
subjects. Platelet poor plasma of patients with cirrhosis (open 
circles) and healthy controls (filled dots) were tested with the 
calibrated automated thrombinography (CAT) assay at 5 pmol/L 
tissue factor, 4 µmol/L phospholipids in the absence or presence 
of 10 nmol/L thrombomodulin (TM). The peak thrombin and ETP 
values in the absence (A) and presence (B) of thrombomodulin 
(TM) are shown. All peak and ETP values both in the absence and 
presence of TM were normalized as the percentage of that of the 
normal pooled plasma (NPP) tested without TM in the sample run. 
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compared to controls, the difference was only on the border of sta-
tistical significance (P = .048). Conversely, a much lower dose of TM 
(10 nmol/L) exhibited a much stronger inhibitory effect on the ETP 
of PPP-TG and the effect was five-fold weaker in the patients than in 
controls. The TM resistance in cirrhosis is most probably due to their 
reduced protein C and protein S, combined with the elevated FVIII 
levels.43-45 The high dose of TM, however, did substantially prolong 
the lagtime of WB-TG in both patients and controls, but this effect 
may be not via the anticoagulant function of the protein C path-
way, but rather because TM prevented thrombin from activating 
platelets and consequently limited the availability of procoagulant 
phospholipids.46
This study has several limitations. First, the number of study 
subjects was relatively low and a heterogenous group of patients 
was included. Second, the age of the cirrhotic patients was higher 
than the healthy controls. However, the effect of age on thrombin 
generation in the general population is modest, and in patients with 
cirrhosis this effect is even smaller as cirrhosis-related distortions 
of the coagulation system outweigh the effects of age on plasma 
levels of coagulation factors.26 This is further supported by our 
observation that older age was counterintuitively correlated with 
longer lagtime and lower peak of WB-TG. Furthermore, due to 
unknown reasons, WB-TG was more resistant to TM than PPP-TG 
despite being used at a high concentration. It is noteworthy that 
Lebreton et al26 reported that plasmatic hypercoagulability of cir-
rhosis patients was detectable only when testing TG with the addi-
tion of TM but not activated protein C. Increased understanding of 
the function of TM in WB-TG is warranted to further optimize the 
TM-modified WB-TG assay for better evaluation of the protein C 
system. Future studies with larger sample size will be needed to ex-
plore the feasibility of this assay to assist coagulation management 
in liver disease patients.
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